Healthcare · Biotechnology · NASDAQ
| Market cap | $12.35B |
|---|---|
| Trailing P/E | 25.1 |
| FCF yield | 5.7% |
| Revenue growth (YoY) | +12.9% |
| EPS growth (YoY) | -10.0% |
| FCF/share growth (YoY) | +50.3% |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
BioMarin Pharmaceutical Inc. trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →
| Member | Chamber | Trade | Amount | Disclosed |
|---|---|---|---|---|
| Daniel Goldman | House | Sell | $1,001 - $15,000 | Apr 3, 2023 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Nov 4, 2020 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Jan 6, 2020 |
| Alan S. Lowenthal | House | Sell | $1,001 - $15,000 | Aug 29, 2019 |
| Alan S. Lowenthal | House | Sell | $506.27 | Aug 29, 2019 |
| Nicholas Van Taylor | House | Sell | $1,001 - $15,000 | Mar 25, 2019 |
| Alan S. Lowenthal | House | Buy | $903.36 | Jun 4, 2018 |
| Alan S. Lowenthal | House | Buy | $1,001 - $15,000 | May 3, 2018 |
| Alan S. Lowenthal | House | Buy | $1,001 - $15,000 | May 2, 2018 |
| Lamar Smith | House | Sell | $1,001 - $15,000 | Mar 5, 2018 |
| Alan S. Lowenthal | House | Buy | $1,001 - $15,000 | Jan 21, 2018 |
| K. Michael Conaway | House | Sell | $1,001 - $15,000 | Sep 15, 2016 |